Patents invented by our employees

No. Publication Nr. Title
1 WO2017153789 Benzo[b]thiophene derivatives and their use for the inhibition of fibroblast growth factor receptor kinases (FGFRs) for the use of neo- and hyperplasia therapies
2 US20160113989 Anticancer and immunomodulating molecules and fractions containing said molecules, and process for preparing said fractions and said molecules from fermented vegetal material, and their uses
3 WO2016042349 New agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders
4 WO2016041972 Benzothiophene, benzyloxybenzylidene and indoline derivatives useful for the treatment of tuberculosis
5 WO2016131789 Benzopyrrolidone derivatives possessing antiviral and anticancer properties
6 CA2882733 Novel 4,6-disubstituted aminopyrimidine derivatives
7 EA201590417 Novel 4,6-disubstituted aminopyrimidine derivatives having both aromatic and halogenic substituents
8 EP2887943 Novel 4,6-disubstituted aminopyrimidine derivatives
9 MX2015002270 Novel 4,6-disubstituted aminopyrimidine derivatives
10 JP2015526479 Novel 4,6-disubstituted aminopyrimidine derivatives
11 US20140057911 Novel 4,6-disubstituted aminopyrimidine derivatives having both aromatic and halogenic substituents
12 WO2014031937 Novel 4,6-disubstituted aminopyrimidine derivatives having both aromatic and halogenic substituents
13 US9040529 4-Phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
14 DK2516405 4-Phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
15 EP2516405 4-Phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
16 ES2558132 4-Phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
17 JP5857211 4-Phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
18 WO2011077171 4-Phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
19 EP3030550 Styryl quinazoline derivatives as pharmaceutically active agents
20 CA2920754 Styryl quinazoline derivatives as pharmaceutically active agents
21 WO2015019121 Styryl quinazoline derivatives as pharmaceutically active agents
22 US2016194291 Styryl quinazoline derivatives as pharmaceutically active agents
23 JP2016529250 Styryl quinazoline derivatives as pharmaceutically active agents
24 EP2837626 Indolinone derivatives as GRK5 modulators
25 WO2015022437 Indolinone derivatives as GRK5 modulators
26 US9169241 Quinolinyloxyphenylsulfonamides
27 AU2010306003 Quinolinyloxyphenylsulfonamides
28 CN102574804  Quinolinyloxyphenylsulfonamides
29 EP2462117 Quinolinyloxyphenylsulfonamides
30 HK1171017 Quinolinyloxyphenylsulfonamides
31 US8685971 Quinolinyloxyphenylsulfonamides
32 WO2011045084 Quinolinyloxyphenylsulfonamides
33 US20150368209 4-Pyrimidinylamino-benzenesulfonamide derivatives and their use for the inhibition of polo-like kinase 1 (PLK1) for the treatment of cancer and their use for the treatment of bacterial infections
34 WO2014106762 4-Pyrimidinylamino-benzenesulfonamide derivatives and their use for the inhibition of polo-like kinase 1 (PLK1) for the treatment of cancer and their use for the treatment of bacterial infections
35 EP2941428 4-Pyrimidinylamino-benzenesulfonamide derivatives and their use for the inhibition of polo-like kinase 1 (PLK1) for the treatment of cancer and their use for the treatment of bacterial infections
36 WO2014106763 Pyridopyrazines as anticancer agents
37 JP2013515047 4-Phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
38 DK2516405 4-Phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
39 EP2516405 4-Phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
40 ES2558132 4-Phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
41 US9040529  4-Phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
42 WO2011077171 4-Phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
43 ES2391373 Quinoline derivatives as axl kinase inhibitors
44 AU2009237938 Quinoline derivatives as axl kinase inhibitors
45 CA2718538 Quinoline derivatives as axl kinase inhibitors
46 CN102131783 Quinoline derivatives as axl kinase inhibitors
47 EP2262772 Quinoline derivatives as axl kinase inhibitors
48 IL208103 Quinoline derivatives as axl kinase inhibitors
49 JP5746015 Quinoline derivatives as axl kinase inhibitors
50 KR101325237 Quinoline derivatives as axl kinase inhibitors
51 MX2010011224 Quinoline derivatives as axl kinase inhibitors
52 RU2010146474 Quinoline derivatives as axl kinase inhibitors
53 US9206130 Quinoline derivatives as axl kinase inhibitors
54 WO2009127417 Quinoline derivatives as axl kinase inhibitors
55 US20120164132 Anticancer and immunomodulating molecules and fractions containing said molecules, and process for preparing said fractions and said molecules from fermented vegetal material, and their uses
56 EP2600721 Anticancer and immunomodulating molecules and fractions containing said molecules, and process for preparing said fractions and said molecules from fermented vegetal material, and their uses
57 WO2012018370 Anticancer and immunomodulating molecules and fractions containing said molecules, and process for preparing said fractions and said molecules from fermented vegetal material, and their uses
58 US20110015214 Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use
59 WO2009104026 Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use
60 EP2257554 Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use
61 US20110318409 Fractions of wheat germ ferment
62 WO2010100515 Fractions of wheat germ ferment
63 EP2403513 Fractions of wheat germ ferment
64 WO2009104027 Therapeutic application of triciclic aromatic and saturated benzo(4,5)thieno-(2,3-d)pyrimidine derivates, as well as their therapeutically acceptable salts
65 US20080187575 Pyrimidine Derivatives
66 CA2578122 Pyrimidine Derivatives
67 EP1786781 Pyrimidine Derivatives
68 JP2008510766 Pyrimidine Derivatives
69 WO2006021458 Pyrimidine Derivatives
70 US20080207677 Napthyridine Compounds As Rock Inhibitors
71 CA2593718 Napthyridine Compounds As Rock Inhibitors
72 EP1833832  Napthyridine Compounds As Rock Inhibitors
73 WO2007060028 Napthyridine Compounds As Rock Inhibitors
74 US20080214583 7h-Pyrrolo[2,3-d]pyrimidine derivatives, as well as their therapeutically acceptable salts, pharmaceutical preparations containing them and process for production the active agent
75 AT462706 7h-Pyrrolo[2,3-d]pyrimidine derivatives, as well as their therapeutically acceptable salts, pharmaceutical preparations containing them and process for production the active agent
76 AU2005238287 7h-Pyrrolo[2,3-d]pyrimidine derivatives, as well as their therapeutically acceptable salts, pharmaceutical preparations containing them and process for production the active agent
77 CA2564277 7h-Pyrrolo[2,3-d]pyrimidine derivatives, as well as their therapeutically acceptable salts, pharmaceutical preparations containing them and process for production the active agent
78 CN1972946 7h-Pyrrolo[2,3-d]pyrimidine derivatives, as well as their therapeutically acceptable salts, pharmaceutical preparations containing them and process for production the active agent
79 EP1756110 7h-Pyrrolo[2,3-d]pyrimidine derivatives, as well as their therapeutically acceptable salts, pharmaceutical preparations containing them and process for production the active agent
80 HU0400891 7h-Pyrrolo[2,3-d]pyrimidine derivatives, as well as their therapeutically acceptable salts, pharmaceutical preparations containing them and process for production the active agent
81 JP2007534737 7h-Pyrrolo[2,3-d]pyrimidine derivatives, as well as their therapeutically acceptable salts, pharmaceutical preparations containing them and process for production the active agent
82 KR20070047737 7h-Pyrrolo[2,3-d]pyrimidine derivatives, as well as their therapeutically acceptable salts, pharmaceutical preparations containing them and process for production the active agent
83 RU2006141393 7h-Pyrrolo[2,3-d]pyrimidine derivatives, as well as their therapeutically acceptable salts, pharmaceutical preparations containing them and process for production the active agent
84 WO2005105804 7h-Pyrrolo[2,3-d]pyrimidine derivatives, as well as their therapeutically acceptable salts, pharmaceutical preparations containing them and process for production the active agent
85 US20070275962 Heterobicyclic Compounds as Pharmaceutically Active Agents
86 AU2004270394 Heterobicyclic Compounds as Pharmaceutically Active Agents
87 CA2572750 Heterobicyclic Compounds as Pharmaceutically Active Agents
88 EP1670804 Heterobicyclic Compounds as Pharmaceutically Active Agents
89 WO2005023818 Heterobicyclic Compounds as Pharmaceutically Active Agents
90 DE60114772 Pharmaceutically active aromatic guanylhydrazones
91 AT308982 Pharmaceutically active aromatic guanylhydrazones
92 AU4057801 Pharmaceutically active aromatic guanylhydrazones
93 EP1255541 Pharmaceutically active aromatic guanylhydrazones
94 ES2250363 Pharmaceutically active aromatic guanylhydrazones
95 US2003203969 Pharmaceutically active aromatic guanylhydrazones
96 WO0156553 Pharmaceutically active aromatic guanylhydrazones
97 WO2006089874 Benzo[2,3]azepino[4,5-b]indol-6-ones
98 US20040171603 Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor
99 WO02094796 Benzo[g]quinoxaline derivatives as effective compounds against infectious diseases
100 AU2002312927 Benzo[g]quinoxaline derivatives as effective compounds against infectious diseases
101 WO0220527 Soluble compounds for the inhibition of multidrug resistance and pharmaceutical compositions thereof
102 AU8613101 Soluble compounds for the inhibition of multidrug resistance and pharmaceutical compositions thereof
103 HU0003554  Soluble peptides which are suitable for stopping multidrog-resistance, pharmaceutical composition comprising thereof and their use
104 US6331555 Treatment of platelet derived growth factor related disorders such as cancers
105 HU226567 Process for producing pharmaceutical compositions containing heptapeptide somatostatin derivatives of neurogene- and non-neurogene-antiflogistic and analgesic activity and peptidomimetica
106 AT307145 Use of phenylhydrazone derivatives as antinflammatory or analgetic agents
107 CA2269995  Process for producing pharmaceutical compositions containing heptapeptide somatostatin derivatives of neurogene- and non-neurogene-antiflogistic and analgesic activity and peptidomimetica
108 DE69927735 Use of phenylhydrazone derivatives as antinflammatory or analgetic agents
109 DK0952159 Use of phenylhydrazone derivatives as antinflammatory or analgetic agents
110 EP0952159 Use of phenylhydrazone derivatives as antinflammatory or analgetic agents
111 ES2251803 Use of phenylhydrazone derivatives as antinflammatory or analgetic agents
112 JP2000001439 Pharmaceutical compositions possessing neurogenic or non-neurogenic anti-inflammatory as well as analgetic effects
113 KR19990083438 Pharmaceutical compositions possessing neurogenic or non-neurogenic anti-inflammatory as well as analgetic effects
114 US6689813 Process for producing pharmaceutical compositions containing heptapeptide somatostatin derivatives of neurogene- and non-neurogene-antiflogistic and analgesic activity and peptidomimetica
115 HU214061 Process for producing phenylamino-acetly-hydrazide derivatives and pharmaceutical compositions containing the said compounds with tumor growth and enzyme-activity inhibiting effect
116 ES2149966 Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor
117 AT192925 Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor
118 AU690958 Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor
119 CA2180658 Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor
120 CN1065744 Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor
121 DE69517054 Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor
122 DK0804191 Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor
123 EP0804191 Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor
124 GR3034215 Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor
125 IL112277 Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor
126 PT804191 Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor
127 US5990141 Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor
128 WO9519169 Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor
129 HU209498 Process for producing 1,4-diazepino/3,4-b/quinasoline-3,7-dione derivatives and pharmaceutically acceptable salts thereof
130 WO9316064 Coumarin derivatives and their analogues inhibiting cell proliferation and tumour growth, pharmaceutical compositions containing them and process for preparing same
131 AU3573893 Coumarin derivatives and their analogues inhibiting cell proliferation and tumour growth, pharmaceutical compositions containing them and process for preparing same
132 HUT63843 Process for producing new kumarin derivatives and their analogs inhibiting mammal cell proliferation and tumour growth, as well as pharmaceutical comkpositions comprising such compounds
133 HU208975 Process for producing imidazo/5,1-b/ quinazolin-9-one derivatives and pharmaceutically acceptable salts thereof, as well as thrombocyta aggregation inhibiting pharmaceutical compositions comprising such active ingredients